Achillion Pharmaceuticals, Inc.

Industry

  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Bioinformatics
See more in Biomedtracker

Latest on Achillion Pharmaceuticals, Inc.

Scrip

AstraZeneca Hopes Danicopan Interim Data Will Prove Sufficient For NDA Filing

 
• By Joseph Haas

AstraZeneca PLC hopes interim data from a Phase III trial of danicopan will be sufficient to file the novel factor D inhibitor for approval to treat extravascular hemolysis (EVH) in patients who take

Scrip

AZ's Alexion Acquisition Looks Astute Bit Of Business

 
• By Kevin Grogan

It would be the biggest acquisition in the company's history but AstraZeneca PLC ’s surprise proposed $39bn takeover of Alexion Pharmaceuticals Inc. looks like a shrewd investment. Observers of the

Scrip

Alexion Buys Out Portola, But Analysts Don’t See Value

 
• By Joseph Haas

Alexion Pharmaceuticals Inc. revealed on 5 May that it has agreed to acquire Portola Pharmaceuticals Inc. for about $1.4bn in cash, but analysts don’t see the value in that price or in Portola’s Fa

Scrip

Apellis Comes Closer To Taking On Alexion In PNH

 
• By Leah Samuel

Cautious optimism greeted the Apellis Pharmaceuticals Inc. announcement of positive Phase III results for its paroxysmal nocturnal hemoglobinuria (PNH) drug pegcetacoplan, including beating Alexion